Drug Profile
VP 025
Alternative Names: VP-025Latest Information Update: 30 Oct 2009
Price :
$50
*
At a glance
- Originator Vasogen
- Developer Intellipharmaceutics International
- Class Anti-inflammatories; Antidementias; Antiparkinsonians; Nootropics; Phospholipids
- Mechanism of Action Cytokine inhibitors; Cytokine modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Alzheimer's disease; Amyotrophic lateral sclerosis; Diabetic retinopathy; Neurological disorders; Parkinson's disease
Most Recent Events
- 22 Oct 2009 Vasogen has merged with IntelliPharmaCeutics Corp to form Intellipharmaceutics International
- 09 Jul 2008 Suspended - Phase-I for Neurological disorders in Canada (unspecified route)
- 09 Jul 2008 Suspended - Preclinical for Alzheimer's disease in Ireland (unspecified route)